Marker Therapeutics (MRKR) Accumulated Depreciation & Amortization (2018 - 2023)
Marker Therapeutics (MRKR) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $6.1 million as the latest value for Q1 2023.
- Quarterly Accumulated Depreciation & Amortization rose 83.71% to $6.1 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Mar 2023, up 83.71% year-over-year, with the annual reading at $5.3 million for FY2022, 92.47% up from the prior year.
- Accumulated Depreciation & Amortization for Q1 2023 was $6.1 million at Marker Therapeutics, up from $5.3 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $6.1 million in Q1 2023, with the low at $10514.0 in Q1 2019.
- Average Accumulated Depreciation & Amortization over 5 years is $2.0 million, with a median of $1.4 million recorded in 2021.
- The sharpest move saw Accumulated Depreciation & Amortization soared 31668.67% in 2019, then soared 83.71% in 2023.
- Over 5 years, Accumulated Depreciation & Amortization stood at $105472.0 in 2019, then skyrocketed by 460.59% to $591264.0 in 2020, then skyrocketed by 363.44% to $2.7 million in 2021, then soared by 92.47% to $5.3 million in 2022, then grew by 15.51% to $6.1 million in 2023.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $6.1 million, $5.3 million, and $4.7 million for Q1 2023, Q4 2022, and Q3 2022 respectively.